Home » Healthcare » Pharmaceuticals » Hepatitis C Treatment Market

Hepatitis C Treatment Market By Drug Type (Interferons, Ribavirin, Direct-Acting Antivirals (DAA) – Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Summary
Table Of Content

Market Insights

Hepatitis C is an inflammatory disease of the liver caused by infection with the hepatitis C virus (HCV). The increasing prevalence of hepatitis C, improved diagnostic techniques, easy availability of treatment medication, and the strong presence of pipeline molecules are driving the growth of the hepatitis C treatment market globally.

The report titled “Hepatitis C Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall hepatitis C treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.

Geographically, the global hepatitis C treatment market is studied for the following regional markets:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hepatitis C treatment market. In-depth analysis of pipeline molecules for key products, such as hepatitis C treatment, and global epidemiology data for hepatitis C have been included in the report. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global hepatitis C treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hepatitis C treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global hepatitis C treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug type, the global hepatitis C treatment market is segmented as follows:

Interferons
Peginterferon alfa-2a
Peginterferon alfa-2b
Interferon alfa-2b
Ribavirin
Direct-acting antivirals (DAA)
Protease Inhibitor
Paritaprevir
Simeprevir
Grazoprevir
Polymerase Inhibitors
Other Drugs

Hepatitis C is an inflammatory disease of the liver caused by infection with the hepatitis C virus (HCV). The medications and duration of HCV treatment depend on a number of factors, such as genotype (the genetic structure of the virus), viral load, degree of liver damage, and ability to tolerate the prescribed treatment. For the purpose of the study, the hepatitis C treatment market is segmented on the basis of drug types, such as interferons, ribavirin, and direct-acting antivirals. It is studied that direct-acting antivirals (DAA) will show significant market growth during the forecast period due to their safety and effectiveness in the treatment of hepatitis C. DAA is a newer approach to treating hepatitis C, and it increases the chance of cure.

Combinations of tablets have a cure rate of more than 90%. Furthermore, due to its target specificity, DAA has fewer adverse effects in the treatment of hepatitis C. Newly approved medications such as Zepatier (elbasvir/grazoprevir), Epclusa (sofosbuvir/velpatasvir), Mavyret (glecaprevir and pibrentasvir), and Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) are expected to show significant market growth during the forecast period.

For the purpose of this study, the global hepatitis C treatment market is categorized into:

North America
Europe
Asia Pacific
Latin America (LATAM)
Middle East and Africa (MEA)

According to the World Health Organization (WHO), approximately 71 million people have a chronic hepatitis C infection. It is known that, in the base year 2016, North America dominated the region in the hepatitis C treatment market in terms of revenue. Factors such as a large number of target populations, the higher cost of treatment medication, technological advances, improved diagnostic techniques, and an upsurge in funding by government agencies in the healthcare system are assisting the growth of the hepatitis C treatment market in North America. According to the Centers for Disease Control and Prevention (CDC), 2.7–3.9 million people in the United States are infected with chronic hepatitis C. It is observed that currently, Europe is the second largest revenue-generating regional market for hepatitis C treatment due to an increase in the prevalence of the disease and high healthcare awareness. The U.K., Germany, and France are major revenue-contributing countries in Europe. It is anticipated that the Asia Pacific market will grow significantly during the forecast period due to populous countries, developing economic conditions, and improving healthcare infrastructure.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hepatitis C Treatment Market Snapshot
2.2 Global Hepatitis C Treatment Market, by Drug Type
2.3 Global Hepatitis C Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Hepatitis C Treatment Market Analysis
3.1 Global Hepatitis C Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Hepatitis C Treatment Drugs
3.4 Global Epidemiology of Hepatitis C
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Hepatitis C Treatment Market

Chapter 4 Global Hepatitis C Treatment Market, by Drug Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Hepatitis C Treatment Market, by Drug Type
4.3 Top 3 Countries
4.4 Interferons
4.4.1 Peginterferon alfa-2a
4.4.2 Peginterferon alfa-2b
4.4.3 Interferon alfa-2b
4.5 Ribavirin
4.6 Direct-Acting Antivirals (DAA)
4.6.1 Protease Inhibitor (Paritaprevir, Simepravir, Grazoprevir)
4.6.2 Polymerase Inhibitors
4.6.3 Other Drugs

Chapter 5 Global Hepatitis C Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AbbieVie Inc.
6.2 Bristol-Myers Squibb Company
6.3 F. Hoffmann-La Roche AG
6.4 Gilead Sciences Inc.
6.5 GlaxoSmith Kline Plc.
6.6 Janssen Pharmaceuticals Inc.
6.7 Merck & Co. Inc.
6.8 Schering AG
6.9 Vertex Pharmaceuticals

List of Figures

FIG. 1 Hepatitis C Treatment Market: Research Methodology
FIG. 2 Global Hepatitis C Treatment Market, by Drug Type, 2016 (US$ Bn)
FIG. 3 Global Hepatitis C Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Hepatitis C Treatment Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Hepatitis C Treatment Market, by Drug type, 2016
FIG. 6 Global Peginterferon alfa-2a Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Peginterferon alfa-2b Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Interferon alfa-2b Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Ribavirin Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Protease Inhibitor Market, 2015 – 2025 (US$ Bn)
FIG. 11 Global Polymerase Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 12 Global Other Drugs Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Hepatitis C Treatment Market
TABLE 2 Global Hepatitis C Treatment Market, by Drug Type, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Hepatitis C Treatment Market, 2015 – 2025 (US$ Bn)
TABLE 4 Global Interferons Market in Hepatitis C Treatment, 2015 – 2025 (US$ Bn)
TABLE 5 Global Direct-Acting Antivirals (DAA) Market, 2015 – 2025 (US$ Bn)
TABLE 6 Global Hepatitis C Treatment Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 7 North America Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 8 North America Hepatitis C Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 9 Europe Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 10 Europe Hepatitis C Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 11 Asia Pacific Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 12 Asia Pacific Hepatitis C Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Latin America Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 14 Latin America Hepatitis C Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 15 Middle East and Africa Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 16 Middle East and Africa Hepatitis C Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 17 AbbieVie Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 18 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 19 F. Hoffmann-La Roche AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 20 Gilead Sciences Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 21 GlaxoSmith Kline Plc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 22 Janssen Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 23 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 24 Schering AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 25 Vertex Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)

Frequently Asked Question

What is the size of Hepatitis C Treatment Market?

The market for Hepatitis C Treatment Market is expected to reach USD$ 65.48 Bn in 2025.

What is the Hepatitis C Treatment Market CAGR?

The Hepatitis C Treatment Market is expected to see significant CAGR growth over the coming years, at 11.3%.

What is the Forecast period considered for Hepatitis C Treatment Market?

The report is forecasted from 2017-2025.

What is the base year considered for Hepatitis C Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

AbbieVie Inc.,Bristol-Myers Squibb Company,F. Hoffmann-La Roche AG,Gilead Sciences Inc.are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –